OmniChart

SMA Jitter 26 Oct 2015

Bug*** Missed out on a bargain this morning.

ARS BuyBAO 26 Oct 2015

sneaked some of these last week before close

ARS BuyBAO 26 Oct 2015

good morning p

MCGN EssentialInvestor 26 Oct 2015

New Chairman Is ex Misys I notice.Misys was bought by private equity firm Vista in 2012.Microgen's Aptitude Software addresses similar end markets.We have been made aware that MCGN has rebuffed one private equity offer this year.

ARS BuyBAO 26 Oct 2015

moving up

CINE oldjoe1 26 Oct 2015

CINE, Detailed Broker Update........ <b>It is Daniel Craig\'s last film as James Bond<i>Canaccord has latched onto Bond-mania with the release of Sceptre, the latest film in the long-running franchise, on Monday to repeat its ‘buy’ rating on cinema chain Cineworld (LON;CINE).But it is the less racy expansion opportunity for the chain in eastern Europe that has got the broker’s juices running.An analysts’ trip to Romania confirmed the commanding position in a growing market held by Cineworld in a country where there is little competition said the broker.Subsidiary Cinema City operates 21 of 34 multiplexes in Romania with plans to take it to 40 multiplexes in the next five years.Cineworld also makes more money per pound of investment in Romania that anywhere else.The 40 multiplex target is realistic, believes Canaccord, as Romania has a population of 20mln and there are 23 cities with a population of over 100,000.James Bond and Star Wars excitement meanwhile has led to problems coping with the demand.Canaccord said Cineworld had confirmed its website had crashed along with its rivals due to the surge of interest, with as many ticket requests for Star Wars in a day as normally come in over three months.Buy with a 620p target price says the broker.</b></i>

SAR fredd1eboy 26 Oct 2015

Results Final ResultsSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce its final results for the year ended 30 June 2015.Operational Highlights· Final preparations to submit CHK1 candidate for two concurrent Phase 1 clinical trials to assess different administration strategies: one as a single agent and the other in combination with chemotherapy.· CHK1 clinical trial applications expected to be submitted in Q1 2016 with trials to commence, subject to approval, shortly thereafter.· Preclinical development of Aurora+FLT3 inhibitor progressing to plan, with toxicology and additional efficacy studies ongoing.· TYK2 inhibitor lead molecule demonstrates striking decrease in psoriasis pathology in a disease model and encouraging results in a rheumatoid arthritis model.Financial Highlights· Net assets at period end were £1.86 million (2014: £1.72 million) of which £1.48 million comprised of cash at bank.· Loss on ordinary activities (after tax credit) of £1,255,368 (2014: Loss of £763,000), an improvement on expectations, reflecting re-phasing of commitments to CHK1 programme.· Successful placing in June 2015 to raise £1.44 million (before expenses) to satisfy ongoing commitments to CHK1 co-development payments and to provide additional working capital.Dr Tim Mitchell, Chief Executive Officer of the Company, said:"Good progress has been made in the last year, with two cancer programmes advancing through preclinical validation and potential new indications for our autoimmune disease programme. With the two planned in-human clinical trials for CHK1 commencing in early 2016, as well as the progress in our other programmes adding further commercial value, we look forward to next year with real anticipation and optimism."

SAB gamesinvestor 26 Oct 2015

Nerves [link] wonder if the offer will be firm by Wednesday?Games

CEB profitprodotcom 26 Oct 2015

Re: Dave Whitby interview Sharepickers -... Good morningI've just listened to the podcast 329 again. Wow some of the wording DW uses really do in still confidence. "My team our collective wisdom really puts us among the best in the business""I'm an experienced guy and have done some good but if the new guy joins us it really will turn some heads, I'm mean this guy. You know it makes me look like a gorilla learning sign language compared to this guy. And if he joins us, and I think he will, I mean this guy will really turn heads and make people sit up and listen "Just a snippet but all I can say is I'm glad I bought more but now I'm feeling I want more again lol. He states the figures he was producing he wants to exceed them by quite some margin so minimum we're looking at 3000bopd. DYOR etc but this is going to be a stormer. It really looks like the real deal. @advfn: 329 - CEB Resources CEO Dave Whitby [link] via @audioBoom

RLD ANS 26 Oct 2015

A helping hand Hi guys, I've been following Richland since Tanzanite days and thought I'd come to the experts for some advice. I bought a couple of large investment grade Tanzanites 66ct cushion and 135ct Oval a few years back and am wondering where the best place to go to sell them would be, and maybe timing as well. I know it's old school and you're now interested in Sapphires but you guys have been around for a while and know better than anyone. Appreciate the insight.

SVE OmarInvestor 26 Oct 2015

Mark to market In the accounts for 30 June 14 which were published a year ago, it mentioned that new accounting rules were coming in which meant that from 1 Oct 15 "mark to market" would have to be used for valuing the portfolio rather than the lower of cost, directors' valuation and market.It was said then that if it had been introduced then the disclosed value of the portfolio would have increased from ~£4 million to ~£6 million.Presumably much of the tumble in the net asset value over the last year has been the collapse of Nordic Energy from ~7p to 1p and (I am guessing here) the Nordic Energy shares will continue to be reported at the same value under the new rules.Presumably the 30 June 15 accounts will be out in the next week or so and we should have some guidance on how they would have looked under the rules which will apply from the Dec 15 interims onwards.OmarOmar

LXB thirty fifty twenty 25 Oct 2015

Re: I'm in thanks TB,that is good to know, there is a fair chance there will be an RNS this week so.Agree that it is not massive in its own right,but it does add a few pennies to NAV,and also increases the success hit rate of mgt,which should thus reduce discount to likely NAV.time will tell......All IMHO, DYOR + BoLLXB is in my top5 hldgs

LXB tiltonboy 25 Oct 2015

Re: I'm in Not announced by the compny yet, but they won their appeal on Truro by a resounding margin. Not a massive deal, but it all adds up.Like tft, I have a target of 120p.

AFRI akaDolly 25 Oct 2015

old news about Lonrho/Rollex They had a website and lots of addresses, and they didnt mind showing you where they were atShiny trucks they have thereC'mon Afri, dont be shy nowwww.lonrho.com/Doc/RollexCompanyProfile.pdf

LXB thirty fifty twenty 25 Oct 2015

Re: I'm in Hi Cagree that at those sorts of prices the share of gain shifts to mgt.personally a final get out at 120p would be a good result - that's 33% from here in 12-18mths (with quite limited downside).its interesting to note that unlike the situation at say LEAF with NAV at 60p there is a £3m provision for the mgt share when CASH is returned. At LXB there used to be a provision I think) from memory a few years ago), but there is none currently and thus I conclude that mgt don't see it likely to reach materially over the strike price - and if they do - good luck to them - its at a much higher level that currently.All IMHO, DYOR + BoLLXB is in my top5 hldgs